Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients.
Kitamura N, Hamaguchi M, Nishihara M, Ikumi N, Sugiyama K, Nagasawa Y, Tsuzuki H, Yoshizawa S, Tanikawa Y, Oshima M, Asatani S, Kobayashi H, Takei M. Kitamura N, et al. Among authors: tsuzuki h. Allergol Int. 2021 Jan;70(1):148-149. doi: 10.1016/j.alit.2020.08.005. Epub 2020 Sep 20. Allergol Int. 2021. PMID: 32967778 Free article. No abstract available.
Successful early introduction of mepolizumab for peripheral neuropathy with a peripheral circulatory disorder in a patient with myeloperoxidase anti-neutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis.
Nishihara M, Hamaguchi M, Ikumi N, Nishiwaki A, Sugiyama K, Nagasawa Y, Tsuzuki H, Yoshizawa S, Tanikawa Y, Asatani S, Kobayashi H, Takei M, Kitamura N. Nishihara M, et al. Among authors: tsuzuki h. Mod Rheumatol Case Rep. 2021 Jul;5(2):354-359. doi: 10.1080/24725625.2021.1916159. Epub 2021 May 10. Mod Rheumatol Case Rep. 2021. PMID: 33970058
Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy.
Kitamura N, Kobayashi H, Nagasawa Y, Sugiyama K, Tsuzuki H, Tanikawa Y, Ikumi N, Okada Y, Takahashi Y, Asai S, Tamura N, Ogasawara M, Kawamoto T, Kuwatsuru R, Tamaki H, Kidoguchi G, Tateishi M, Kimura M, Mochida Y, Harigane K, Shimazaki T, Koike T, Tanimura K, Kataoka H, Amano K, Yasuoka H, Takei M. Kitamura N, et al. Among authors: tsuzuki h. Int J Rheum Dis. 2023 Jun;26(6):1058-1066. doi: 10.1111/1756-185X.14695. Epub 2023 Apr 14. Int J Rheum Dis. 2023. PMID: 37058849
219 results